Gimv, Samsara Biocapital and Lightspeed Venture Partners ed a $74m Series B funding round in ImmunOs Therapeutics.

Gimv, a Belgian European investment company, Samsara Biocapital, a venture capital firm, and Lightspeed Venture Partners, a global venture capital firm, led a $74m Series B funding round in ImmunOs Therapeutics, a biotech company focused on a new class of HLA-based therapies for the treatment of cancer and autoimmune diseases. “ImmunOs’ approach of identifying HLA molecules with naturally optimized affinity and specificity profiles is not just elegant but also truly differentiated – a novel modality leveraging the co-evolution of immune-regulatory mechanisms. We are extremely excited by the progress being made at ImmunOs and proud to support the team towards clinical validation for the benefit of patients,” Andreas Jurgeit, Gimv Partner.